BioSpace News Archive

Phio Pharmaceuticals Corp. (Nasdaq: PHIO), today presented a trial-in-progress poster describing the study outline of its Phase 1b clinical trial of PH-762, a self-delivering RNAi targeting PD-1, for the treatment of advanced melanoma at the 2022 American Society of Clinical Oncology (ASCO) annual meeting.

Liminal BioSciences Inc. announced the voting results from its Annual General Meeting of Shareholders held virtually on June 6, 2022.

Concert Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 10,000,000 shares of its common stock to the public at $4.75 per share.

Editas Medicine, Inc. announced the grant of inducement awards to the Company’s newly appointed President and Chief Executive Officer, Gilmore O’Neill, M.B., M.M.Sc.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2022 Jefferies Global Healthcare Conference.

Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today detailed the results of its Phase 2 clinical trial (Study RM-202) of rivoceranib, an orally administered tyrosine kinase inhibitor (TKI), in patients with progressive recurrent or metastatic adenoid cystic carcinoma (R/M ACC).

Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), today presented data from its Phase 1 trial of dapiglutide at the 82nd Scientific Sessions of the American Diabetes Association (ADA) in New Orleans and announced it will be supporting a Phase 2 investigator-initiated clinical trial of dapiglutide in obesity anticipated to commence by early 2023.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company highlighted its pipeline advances in immunotherapy drugs, including anti-PD-1 monoclonal antibody toripalimab and anti-BTLA monoclonal antibody icatolimab (TAB004/JS004).

iNtRON Biotechnology (“iNtRON” or “Company”) announced today that the company has successfully completed the GLP toxicology studies of BAL200.

Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.